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Background Topical corticosteroids are used extensively to treat inflammatory skin
disorders including atopic dermatitis (AD). Several studies have described tem-
porary reversible suppression of hypothalamic–pituitary–adrenal function. How-
ever, sound evidence of permanent disturbance of adrenal gland function is
lacking.
Objectives To relate basal cortisol levels to prior use of topical corticosteroids and
disease activity in patients with moderate to severe AD and to investigate the
effect on basal serum cortisol levels of topical corticosteroid treatment during
hospitalization.
Methods Two groups of patients with AD were evaluated: 25 inpatients with severe
AD who required hospitalization (group 1) and 28 outpatients with moderate to
severe AD (group 2). In group 1, morning basal serum cortisol levels were meas-
ured twice, at admission and at discharge; in group 2, morning basal serum cort-
isol levels were measured once. Use of topical corticosteroids in the 3 months
prior to the cortisol measurement was recorded and disease activity was monit-
ored using the Six Area, Six Sign Atopic Dermatitis (SASSAD) score and serum
thymus and activation-regulated chemokine (TARC) levels.
Results On admission, basal cortisol levels in group 1 were significantly
(P < 0Æ001) decreased in 80% of the patients. In group 2, the basal cortisol
levels were normal in all but three patients. Comparing the two groups, group 1
on admission had a significantly lower cortisol level than that of group 2
(P < 0Æ001). Disease activity in group 1 on admission was significantly higher
than that of group 2 (P < 0Æ001). There was no difference in use of topical cor-
ticosteroids in the 3 months before cortisol measurement. At discharge in group
1 there was a significant increase (P < 0Æ0001) of basal cortisol levels and a sig-
nificant (P < 0Æ001) decrease in disease activity reflected by the decrease in
serum TARC levels and SASSAD score.
Conclusions Disease activity, rather than the use of topical corticosteroids, is respon-
sible for the low basal cortisol values in patients with severe AD.
For many decades topical corticosteroids have been widely
used to treat inflammatory skin disorders including atopic der-
matitis (AD). Although dermatologists and general practition-
ers often prescribe topical corticosteroids, there is widespread
concern about possible systemic side-effects, such as depres-
sion of adrenal gland function, osteoporosis, growth impair-
ment in children, glaucoma and cataract. Corticophobia (fear
of topical corticosteroid use) by patients and doctors often
results in inadequate disease control in patients with inflam-
matory skin disorders.
The original active topical glucocorticosteroid is hydrocorti-
sone, the natural glucocorticosteroid of the adrenal cortex.
Shortly after its introduction as a treatment for inflammatory
skin diseases, Malkinson and Ferguson1,2 found experimental
evidence that some percutaneous absorption of hydrocortisone
may occur. However, several years later, Fleischmajer3 found
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no evidence of systemic effects after application of large
amounts of hydrocortisone in 19 patients with AD (age 5–
60 years). In children with AD, percutaneous absorption of
hydrocortisone was proven to be significantly lower in the
convalescent phase of the disease compared with the acute
phase, probably owing to the restoration of the skin barrier.4
Several years after the introduction of hydrocortisone, new
synthetic corticosteroids were developed. Synthetic corticoster-
oids can modulate endogenous cortisol secretion by influen-
cing hypothalamic and pituitary effects on adrenal gland
activities through the hypothalamic–pituitary–adrenal (HPA)
axis.5 The presence of synthetic corticosteroids in the circula-
tion exerts a negative feedback on the release of hypothalamic
corticotropin-releasing hormone (CRH). Diminished CRH
release results in a decrease in corticotropin (ACTH) release
from the pituitary gland, which in turn leads to decreased
production of endogenous cortisol by the adrenal gland.
As early as 1965, Scoggins and Kliman6 concluded that the
cortisol content of plasma in the early morning proved to be a
very sensitive index of the suppression of pituitary–adrenal
function by synthetic corticosteroid analogues. Nowadays,
measuring total basal serum cortisol (between 08.00 and
09.00 h) is still the most commonly used method for the
initial evaluation of adrenal gland function. Although there is
convincing evidence that percutaneous absorption of topical
corticosteroids can occur, especially using potent topical corti-
costeroids on large areas of inflamed skin and for longer peri-
ods, the question remains whether this is relevant in clinical
practice. Several studies and case reports describe temporary
reversible suppression of HPA function,5,7 but there is no cir-
cumstantial evidence of permanent disturbance of adrenal
gland function. When treating patients with severe AD it is
important to estimate the risk–benefit ratio when using potent
topical corticosteroids, because the alternative treatment
options in this patient group, such as oral immunosuppressive
drugs, also have side-effects when used for extended periods.
The aim of the current study was to investigate basal serum
cortisol levels of adult patients with moderate to severe AD in
relation both to the total amount of topical corticosteroid used
in the past 3 months and to the disease activity. In addition,
the effect was investigated of intensive topical corticosteroid
treatment on basal serum cortisol level and disease activity in
patients with severe AD during admission to hospital.
Patients and methods
Patients
Fifty-three patients with moderate to severe AD were studied.
The inpatients (group 1) consisted of 25 patients (11 men
and 14 women, age range 18–83 years; mean age 39) with
severe uncontrolled AD that required hospitalization. Twenty-
eight outpatients (12 men and 16 women, age range 18–
74 years; mean age 36) with moderate to severe but
controlled AD served as a control group (group 2). The diag-
nosis of AD was made according to the criteria of Hanifin and
Rajka.8 None of the patients were pregnant at inclusion.
Menopausal state (including use of oestrogen replacement
therapy), use of oral contraception, use of antidepressants,
mean intake of alcohol per week, height and weight were
recorded on inclusion. The potency of topical corticosteroids
used was rated as class 1, 2, 3 or 4; class 1 is the least potent
and class 4 is the most potent. Both groups used topical corti-
costeroids of class 2, 3 or 4 prior to evaluation. The local
medical ethical committee approved this study.
Basal cortisol levels
Basal serum cortisol levels were determined between 08.00
and 09.00 h in group 1 (on first day of admission) and group
2 using the automated immunoanalyser Advia Centaur (Bayer
HealthCare, Mijdrecht, the Netherlands). Total imprecision
over the range 0Æ1–0Æ9 lmol L)1 was 7Æ5–10%. In group 1,
measurement of the basal cortisol level was repeated on the
morning of discharge. To be sure that we solely measured
endogenous cortisol levels in the assay used, we tested the
cross-reactivity of the various corticosteroids administered
with the assay used.
Disease activity
In group 1, disease activity was recorded on the first day of
admission and on the day of discharge using the Six Area, Six
Sign Atopic Dermatitis (SASSAD) score9 and by determin-
ing the level of serum thymus and activation-regulated
chemokine (TARC/CCL17).10–12 In group 2, the disease activ-
ity was also recorded (on a visit to the outpatient clinic) using
the SASSAD score and by measuring the level of TARC in peri-
pheral blood.
Topical corticosteroid use
In both groups, the use of topical, inhaled and systemic corti-
costeroids was evaluated for the period of 3 months prior to
admission or visit to the outpatient clinic. This was carried out
using a combination of the patient’s history and pharmacy
records obtained. We strove as accurately as possible to quan-
tify the exact amount of topical corticosteroid used. Using this
method, we anticipate that there is an overestimation of the
actual use of topical corticosteroids as not all patients use the
topical steroids they obtain from the pharmacy and/or accu-
rately estimate their use. The topical corticosteroid use is
expressed as the total amount (in g) used over the 3 months
prior to measurement of basal cortisol levels. During admission
(group 1), we did not impose a previously specified treatment
regimen and patients were treated as they would have been
otherwise. We subsequently recorded this treatment modality.
Statistical analysis
Statistical analysis was performed using the program SPSS for
Windows (version 12, 2003; SPSS Inc., Chicago, IL, U.S.A.).
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Because clearly skewed distributions in outcome parameters
were observed, nonparametric tests were used. Associations
between variables were tested in contingency tables using
Fisher’s exact test or the v2 test (with Yates’ continuity correc-
tion). Differences in median values between independent vari-
ables were tested using the Mann–Whitney test or the
Kruskal–Wallis test (corrected for tied values). The Spearman
rank correlation test was used to measure correlations between
variables. Probability levels of 0Æ05 and below were consid-
ered significant.
Results
Group 1 (admission) vs. group 2
Basal cortisol levels
The clinical characteristics of the patients are summarized in
Table 1. Basal cortisol levels on admission in the inpatients
(group 1) were significantly (P < 0Æ001) decreased in 20 of
the 25 patients (80%), including six of seven patients using
oral contraceptives. Mean cortisol levels at admission were
0Æ087 lmol L)1 lower than the lower limit of the reference
range for cortisol (0Æ20 lmol L)1) [95% confidence interval (CI)
of difference 0Æ018–0Æ157] (P < 0Æ05). In the outpatients (group
2), basal cortisol levels were normal (> 0Æ20 lmol L)1) in all
but three patients.
Comparing the two groups, the basal cortisol levels of
group 1 patients at admission were significantly lower than
those of group 2 (P < 0Æ001). The mean ± SD difference
between the mean basal cortisol levels of group 1 (at admis-
sion) and group 2 is 0Æ374 ± 0Æ06 lmol L)1 (95% CI of
difference 0Æ254–0Æ494) (Fig. 1a). This difference is also
significant when correcting for use of oral contraceptives.
Testing the assay, the basal cortisol levels measured were
not influenced by the addition of the various synthetic cortico-
steroids and it can be concluded that there is no cross-reactivity
in this assay.
Disease activity
Disease activity in group 1 on admission was significantly
(P < 0Æ001) higher than the disease activity in group 2 as
indicated by a higher level of TARC in group 1 with a
mean ± SD of 5037 ± 5841 pg mL)1 (95% CI 2511–7563)
vs. a mean ± SD in group 2 of 1391 ± 2005 pg mL)1 (95%
CI 581–2201) (Fig. 1b) and by a significantly (P < 0Æ001)
higher mean ± SD SASSAD score in group 1 of 41 ± 16 (95%
CI 33–49) vs. a score in group 2 of 19 ± 8 (95% CI 15–22).
Topical corticosteroid use
There was no significant difference in the amount of topical
corticosteroids used between the two groups in the 3 months
Table 1 Clinical characteristics of the patients
Group 1 (inpatients
at admission) (n ¼ 25)
mean ± SD
Group 2
(outpatients) (n ¼ 28)
mean ± SD
Age (years) 39 ± 16 36 ± 15
Sex (men/women) 11/14 12/16
Duration of hospitalization (days) 19 ± 5 –
SASSAD score 41 ± 16 (n ¼ 17) 19 ± 8 (n ¼ 24)
TARC level (pg mL)1) 5037 ± 5841 1391 ± 2005
Use of topical corticosteroidsa
g per week 28 ± 13 27 ± 22
g per 3 months 339 ± 151 326 ± 258
Potency of topical corticosteroids usedb,c
Class 2/3 8 8
Class 3 12 14
Class 3/4 5 5
Class 4 0 1
Use of inhaled/oral corticosteroidsb 8 9
Use of oral corticosteroidsb 5 9
Body mass index (kg m)2) 23Æ4 ± 4Æ0 23Æ5 ± 3Æ4
Use of antidepressantsb 2 1
Alcohol consumption (units per week) 6 ± 7 4 ± 5
Postmenopausal women/oestrogen therapy 2/0 3/0
Use of oral contraceptives 7 5
SASSAD, Six Area, Six Sign Atopic Dermatitis; TARC, thymus and activation-regulated chemokine. aUse in the 3 months before cortisol mea-
surement. bUse in the 3 months before cortisol measurement, expressed in numbers of patients. cThe potency of topical corticosteroids used
was rated as class 1, 2, 3 or 4; class 1 is the least potent and class 4 is the most potent.
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prior to basal cortisol measurement. Group 1 had used
339 ± 151 g (mean ± SD) in 3 months and group 2 had
used 326 ± 258 g (mean ± SD) of topical corticosteroids in
3 months (P ¼ 0Æ8), with a mean difference of 12 g [SEM
60Æ2 and 95% CI ()133)–109]. There was no significant dif-
ference between group 1 and 2 in potency of topical cortico-
steroids used (P ¼ 0Æ963), use of inhaled corticosteroids
(P ~ 1) and use of oral corticosteroids in the 3 months prior
to inclusion (P ¼ 0Æ365) (Table 2).
Within-group comparison
No significant correlation was found between the basal corti-
sol levels and use of topical corticosteroids in groups 1 and 2
(P ¼ 0Æ287 and P ¼ 0Æ181, respectively; Spearman rank corre-
lation test). In addition, there was no association between the
basal cortisol levels and the potency of topical corticosteroids
used (P ¼ 0Æ787 for group 1 and P ¼ 0Æ182 for group 2;
Kruskal–Wallis test), use of inhaled corticosteroids (P ¼ 0Æ514
for group 1 and P ¼ 0Æ418 for group 2; Mann–Whitney test)
and use of oral corticosteroids (P ¼ 0Æ329 for group 1 and
P ¼ 0Æ634 for group 2; Mann–Whitney test). Furthermore,
there was no significant difference in body mass index, num-
ber of patients using antidepressants, alcohol intake per week,
number of postmenopausal women and number of women
using contraceptives between the two groups (Table 1).
Group 1: effect of hospitalization
In group 1 there was a significant increase during treatment
in hospital (P < 0Æ0001) of basal cortisol levels in compari-
son with the admission values, with a mean increase of
0Æ39 lmol L)1 (95% CI 0Æ26–0Æ52) (Fig. 2a). This increase
was less but still significant (P < 0Æ001) when correcting for
oral contraceptive use, with a mean increase of 0Æ26 lmol L)1
(95% CI 0Æ16–0Æ37). At discharge, the serum TARC levels
had significantly (P < 0Æ001) decreased in comparison with
admission, with a mean decrease of 2900 pg mL)1 (95% CI
1542–4261) (Fig. 2b). The mean ± SD SASSAD score of
this group on admission was 41 ± 16 and at discharge
the SASSAD score had decreased significantly to 9 ± 5
(P < 0Æ001). There was no difference in effect between the
different treatment modalities used during hospitalization in
group 1 on the rise in basal cortisol levels (Table 3). At dis-
charge in group 1 there were four patients who still had
basal cortisol levels below the lower limit of the reference
range (0Æ20 lmol L)1); however, 6 weeks after discharge
they too increased to normal levels.
Group 1 (discharge) vs. group 2
Comparing the two groups again, this time comparing group
1 at discharge with group 2, neither the mean basal cortisol
levels nor the serum TARC levels differed significantly (P ¼
0Æ846 and P ¼ 0Æ409). The difference in cortisol was also not
significant when correcting for use of oral contraceptives. The
difference in the mean basal cortisol level at discharge in
group 1 (mean ± SD 0Æ50 ± 0Æ31 lmol L)1) and group 2
(mean ± SD 0Æ49 ± 0Æ25 lmol L)1) is 0Æ015 lmol L)1 [SEM





































Fig 1. (a) Basal cortisol levels on admission
in group 1 (inpatients) compared with basal
cortisol levels in group 2 (outpatients)
(log scale). Horizontal lines indicate median
values. The dashed line at 0Æ2 lmol L)1 is the
lower limit of the reference range. (b) Serum
thymus and activation-regulated chemokine
(TARC) levels on admission in group 1
(inpatients) compared with TARC levels in
group 2 (outpatients) (log scale). Horizontal
lines indicate median values.
Table 2 Comparison of the inpatient group and outpatient group in
use of topical, inhaled and oral corticosteroids and potency of topical
corticosteroids used
Steroid use in 3 months prior
to cortisol measurement Group 1 vs. group 2
Mean amount of topical
corticosteroids in g
P ¼ 0Æ8
Inhaled corticosteroids (yes/no) P ~ 1
Oral corticosteroids (yes/no) P ¼ 0Æ365
Potency of topical corticosteroids
(class 2–4)
P ¼ 0Æ963
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mean TARC level is 699 pg mL)1 [SEM 836 pg mL)1, 95% CI
()998)–2396].
Discussion
In this prospective, parallel cohort study we have demonstra-
ted that low basal serum cortisol values are not caused by
prior use of potent topical corticosteroids in patients with
moderate to severe AD. Within both the inpatient and out-
patient groups, no significant correlation was found between
the amount of topical corticosteroids used and basal serum
cortisol values. Furthermore, in the inpatient group (group 1)
with active disease, significantly lower basal serum cortisol
levels were found compared with the outpatient group (group
2) with controlled disease, whereas there was no significant
difference in topical corticosteroid use in both groups. Nota-
bly, basal serum cortisol levels of the inpatients showed a dra-
matic increase during intensive treatment with large amounts
of potent topical corticosteroids.
The results of our study invalidate overall opinion that treat-
ment with potent topical corticosteroids suppresses function
of the HPA axis. In the past, many studies have been per-
formed linking the use of topical corticosteroids to HPA axis
dysfunction, with contradictory results. Although there seems
to be laboratory evidence of reversible suppression of the HPA
axis in patients treated with topical corticosteroids, irreversible
adrenal insufficiency is found only in rare cases.13 One of the
limitations of most studies is that they were not primarily
designed to study HPA axis function. Most studies show retro-
spective data and no information is given on disease severity
at the moment of testing nor on the amount of topical corti-
costeroids used before testing. Although this study was
designed primarily to relate topical corticosteroid use and dis-
ease activity to basal serum cortisol levels, its limitation prob-
ably lies in the difficulty of exactly quantifying the amount of
topical corticosteroids used by patients in the weeks prior to
measurement of basal serum cortisol level. Weighing the corti-






































Fig 2. (a) Basal cortisol levels on admission
and on discharge in group 1 (inpatients)
(log scale). Horizontal lines indicate median
values. The dashed line at 0Æ2 lmol L)1 is the
lower limit of the reference range. (b) Serum
thymus and activation-regulated chemokine
(TARC) levels on admission and discharge in
group 1 (inpatients) (log scale). Horizontal
lines indicate median values.




patients (n ¼ 25)
Basal cortisol levels (lmol L)1)
Admission Discharge
Topical corticosteroids 13 0Æ10 ± 0Æ16a 0Æ44 ± 0Æ29a
Topical corticosteroids under occlusion 2 < 0Æ01 0Æ12
0Æ04 1Æ13
Tar preparations 3 0Æ1 0Æ30
0Æ18 1Æ11
0Æ59 0Æ73
Tar preparations and topical 2 0Æ07 0Æ81
corticosteroids 0Æ39 0Æ36
Oral immunosuppressants and topical corticosteroids
Ciclosporin 3
Prednisone 1 0Æ03 ± 0Æ009a 0Æ46 ± 0Æ16a
Prednisone and azathioprine 1
aMean ± SD.
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patients forgot their tubes and often did not know what they
had received from the pharmacy. Using the pharmacy records
in combination with the patient’s history, there was probably
an overestimation of the actual use of topical corticosteroids.
If this maximal amount of topical corticosteroids has no effect
on the basal cortisol level, it is safe to reason that the actual
amount used by patients certainly has no effect.
Several safety studies concerning the HPA axis were per-
formed after the introduction of a potent topical corticosteroid,
clobetasol-17-propionate. Olsen and Cornell14 demonstrated
that clobetasol-17-propionate could induce a dose-related
depression of cortisol level in hospitalized patients, with
recovery of cortisol levels within 2 or 3 days after discontinu-
ation. By contrast, Jegasothy et al.15 found serum cortisol levels
below the normal limit in only seven of 113 outpatients with
AD or psoriasis who were treated with clobetasol ointment
two or three times daily (up to 50 g weekly) on two consecu-
tive weeks. Cushing syndrome caused by the use of large
amounts of clobetasol propionate 0Æ05% ointment during long
treatment periods was described in two cases.16 Because
patients did not regularly visit a doctor, there was an inappro-
priate use or abuse of this potent topical steroid in both cases.
In an efficacy study, using fluticasone propionate ointment in
adult patients with moderate to severe AD, van der Meer
et al.17 also evaluated basal serum cortisol levels in a subgroup
of patients for a longer period. No significant changes in basal
serum cortisol were detected during the induction phase of
4 weeks (intensive topical corticosteroid use, n ¼ 79), nor
in the controlled maintenance phase of 16 weeks (topical
corticosteroid use twice weekly, n ¼ 13).
Children are believed to be especially at risk for systemic
effects of topical corticosteroids, because of their relatively
large body surface. Patel et al.18 studied the adrenal function in
14 prepubertal children with moderate to severe AD (age 3–
10 years). No difference was found in basal serum cortisol
levels between children with moderate to severe AD regularly
treated with topical corticosteroids compared with controls. In
a more recent open-label safety study on the effect of flutica-
sone propionate cream 0Æ05% twice daily over 3–4 weeks in
51 children with moderate to severe AD, no effect on basal
serum cortisol levels was seen.19
Evidence that factors other than topical corticosteroid use are
responsible for aberrant HPA axis activity in patients with AD
comes from a study of Matsuda et al.,20 in which children with
AD (age 2–18 years) who did not use topical corticosteroids
before evaluation were compared with children who had rou-
tinely used topical corticosteroids. Although no significant dif-
ference in basal serum cortisol was found between the two
groups, basal cortisol levels and the response to ACTH of the
total AD group were significantly lower compared with controls.
If low basal serum cortisol is not linked to prior use of top-
ical corticosteroids, what can be the reason for this observa-
tion? Matsuda et al. demonstrated that topical corticosteroid
treatment during hospitalization in a group of children with
AD who had not previously been treated with topical cortico-
steroids resulted in a significant decrease in disease activity
that was paralleled by a significant increase in basal serum
cortisol. These findings are in accordance with our own results
showing that the significant decrease in disease activity after
intensive treatment with large amounts of potent topical corti-
costeroids during the hospitalization period resulted in a con-
siderable increase (normalization) in basal serum cortisol
levels. It would appear that HPA axis function is influenced
more by disease activity than by systemic effects of potent
topical corticosteroids. This hypothesis is further supported by
the fact that the patients with severe and extensive disease
who needed hospitalization (inpatient group) used as little as
30 g topical corticosteroids weekly before their admission,
whereas their basal serum cortisol was below the lower limit
of the reference range for cortisol in 80% of the patients. Dur-
ing hospitalization, when potent topical corticosteroids were
applied by dermatological nurses, approximately 25 g twice
daily was used during the first week (approximately 350 g
weekly) in the acute phase and once daily in the convalescent
phase (approximately 150–175 g weekly). Despite the fact
that some percutaneous absorption must have taken place,
morning serum cortisol levels increased. The data from our
study and those of Matsuda et al. suggest that disease activity is
linked to low basal serum cortisol levels. This is of special
interest because appropriate reactivity of the HPA axis to
stressful stimuli, such as inflammation, may be necessary to
control immunological processes. During inflammatory pro-
cesses, the release of proinflammatory cytokines, such as inter-
leukin (IL)-1b, tumour necrosis factor-a and IL-6, stimulates
the HPA axis to produce larger amounts of glucocortico-
ids.21,22 The increased adrenal glucocorticoid production can
suppress inflammatory responses, thus preventing chronicity.
Data from animal studies also suggest that the HPA axis might
play a protective role in chronic inflammation.23
Interestingly, attenuated responsiveness of the HPA axis in
adults and children with AD who were corticosteroid free for
at least 3 months was found by Buske-Kirschbaum et al.24,25
Significantly attenuated cortisol and ACTH responses to a stan-
dardized laboratory psychological stressor were found in AD
patients compared with nonatopic controls, whereas basal
serum cortisol levels were comparable. The possible existence
of a defective HPA axis has been studied extensively in rheu-
matoid arthritis (RA). Several small studies indicate a possible
inability to mount adequate cortisol responses to inflamma-
tion. In a recent study of 50 patients with RA, Eijsbouts et al.22
demonstrated that under the standardized conditions of the
insulin tolerance test, patients with RA have decreased plasma
cortisol levels compared with healthy controls, despite elevated
levels of IL-6 in these patients. Because there was no differ-
ence in ACTH levels, the authors suggest that reduced HPA
axis responsiveness may be due to a defect located at the adre-
nal level; this contrasts with what is suggested by the data of
Buske-Kirschbaum et al.24 in patients with AD. In addition,
decreased activity of the HPA axis has been found in other
chronic inflammatory diseases, such as Crohn disease.26
The results of our study suggest that disease activity rather
than topical corticosteroid use is responsible for the low basal
 2007 The Authors
Journal Compilation  2007 British Association of Dermatologists • British Journal of Dermatology 2007 156, pp979–985
984 Low basal serum cortisol in atopic dermatitis, I.M. Haeck et al.
serum cortisol levels in patients with severe AD. This hypothe-
sis is supported by data from the literature, linking chronic
inflammatory diseases, such as AD, RA and inflammatory
bowel disease, to attenuated HPA axis responsiveness.
Measuring basal serum cortisol has its limitations as it
only reflects what occurs at the level of the adrenal gland. In
addition, no information is available on the responsiveness of
the adrenal gland upon stimulation. A low basal cortisol level
does not automatically mean that the gland is not responsive
to stimulation. Further research is necessary to establish if only
the adrenal gland is affected or if the suppression of this axis
also takes place higher, at the level of the pituitary gland
and/or hypothalamus. The results of Buske-Kirschbaum et al.24
suggest that the latter could well be the case in patients with
AD.
These findings have major implications for daily practice
when treating patients with moderate to severe AD. Although
percutaneous absorption of potent topical corticosteroids is
likely to occur, especially during the acute phase in severe AD,
the suppressive effect on adrenal gland function seems to be
overruled by the positive effect of adequate disease control.
Bearing these results in mind, doctors should worry more
about the effect of inadequate disease control than the possible
side-effects of potent topical corticosteroids.
Finally, we advise measuring basal serum cortisol levels in
patients with severe AD with uncontrolled disease, with fol-
low-up measurements during treatment. When basal serum
cortisol levels remain below normal level despite adequate
treatment, corticosteroid supplementation during stressful
events, such as operations, fever or after a trauma, is advised.
Further studies are needed to investigate whether attenuation
of the HPA axis precedes chronic inflammation in AD or can
be regarded as a result of chronic inflammation.
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